The Telangana State Drugs & Cosmetics Control Department (TG SAFE) issued a public advisory on October 14, 2026 warning consumers and healthcare providers about unapproved peptides sold online, including BPC-157, GHK-Cu, retatrutide, and tesamorelin.
The advisory states that these products are being marketed as research chemicals labeled “Not for Human Consumption” yet come with instructions for human use. TG SAFE directed registered medical practitioners and healthcare professionals not to procure, prescribe, or administer unapproved products for weight-loss treatment or other indications in violation of applicable regulations.
The advisory signals growing regional regulatory attention toward online peptide sellers and practitioners administering unapproved products, extending scrutiny beyond federal-level oversight. It is a public advisory, not a formal enforcement action.
What happened
TG SAFE, the state-level drug regulatory authority in Telangana, India, published a public advisory identifying several peptides being sold through online channels without regulatory approval. The named products include BPC-157, GHK-Cu, retatrutide, and tesamorelin.
According to the advisory, some of these products carry labels stating “Not for Human Consumption” while simultaneously being sold with instructions for human use. The regulator warned that purchasing and using such products poses health risks to consumers.
TG SAFE also directed registered medical practitioners and healthcare professionals not to procure, prescribe, or administer these unapproved products for weight-loss or other indications, citing violations of applicable drug regulations.
Why it matters
This advisory demonstrates that state-level drug regulators in India are actively moving against the online peptide distribution ecosystem, not just federal authorities. The action creates legal and commercial risk for peptide distributors, online sellers, and telehealth platforms operating in the region.
The named peptides — BPC-157, GHK-Cu, retatrutide, and tesamorelin — have gained visibility in online markets, often marketed for weight loss, recovery, and anti-aging purposes. The advisory’s specific instruction to healthcare providers not to prescribe or administer these products signals that regulators are directing attention across the supply chain, from sellers to prescribers.
However, the action is an advisory rather than a formal enforcement measure. No product seizures or named practitioners were reported in connection with the announcement.
What to watch next
- Whether TG SAFE or other Indian state regulators follow the advisory with formal enforcement actions such as seizures, license actions, or prosecutions.
- How telehealth platforms and online peptide sellers operating in India respond to the advisory, including any changes to product offerings or marketing practices.
- Whether other Indian states issue similar advisories targeting unapproved peptides sold online.
- Potential responses from healthcare providers who may have been prescribing or administering the named peptides.
Sources
Industry information only. Not medical or legal advice.
